Abstract 3366
Background
The microbiota community is considered as an organ of the human body. Recent studies have found that dysbiosis may have an impact on the interaction between immune regulation and tumor treatment. The main objective of this study is to characterize the gut microbiota in patients with non-small cell lung cancer (NSCLC) in advanced stages, and its relationship with obesity, smoking habits, clinical pathological features and response to treatment with immune-checkpoints blockers (ICB).
Methods
16S rRNA gene sequencing was performed on 48 stool samples from advanced NSCLC patients prior to treatment with ICB (PD-1 inhibitor and PD-L1 inhibitor). The database used for the taxonomic assignation was the SILVA_release_132. The parametric statistical analysis was performed in SPSS package (15.0). A p-value <0.05 was considered statistically significant for all analyzes.
Results
The average age of the 48 patients was (64±10 years), of which 36 patients were male, 27 patients present PD-L1 positive, 28 patients with smoking habits. 261 different genus were detected in all the samples, being Bacteroides 28.11%, Alistipes 6.58% and Prevotella 4.67% the more frequently found. Non-smokers presented significantly higher richness and diversity (Chao1 p = 0.001, Shannon p = 0.001, Simpson p = 0.03) compared with current and former smokers. Greater abundance of genus Blautia was associated with obesity (p = 0.043). In addition, according to histology, greater abundance of genus Odoribacter was observed in squamous cell carcinoma patients compared to adenocarcinoma (p = 0.04); and regarding stage, stage IIIB patients presented higher proportion of genus Lactobacillus than stage IV (p = 0.017).Patients with progression disease to the ICB treatment presented significantly higher abundance of genus Ruminococcaceae_UCG-013 (p = 0.019).
Conclusions
We have been demonstrated a potential relationship between the gut microbiota in NSCLC patients and clinical-pathological features, which requires confirmation in a larger study. The more relationship with the ICB is under evaluation and will be presented at the meeting. Funded by CB16/12/00350 from CIBEROnc, PI18/00226, and PI15-00753 from ISCIII.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fundación Investigación Hospital General Universitario Valencia.
Funding
CIBEROnc, Instituto de Salud Carlos III.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract